Europe’s doors remain open for Ariad Pharma’s leukemia drug Iclusig. PMLive reported Monday that the European Medicines Agency says the drug can stay on the market, but the EMA is restricting the eligible patient population.
Ariad has said since halting US marketing and distribution that it expects the overall fallout will be that the FDA requires a more restricted label, meaning a smaller patient group. The FDA asked the company to stop drug-related operations over concerns that it could be associated with blood clots.
The company has retrenched since cutting its US push in October by both laying off 40% of its staff and pursuing a streamlining effort that will cut costs by 35% and power the company through the middle of 2015.